Compare · RVMD vs WWB
RVMD vs WWB
Side-by-side comparison of Revolution Medicines Inc. (RVMD) and Windward Bio Group AG (WWB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVMD and WWB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $34.57B, about 25.6x WWB ($1.35B).
- RVMD has been more active in the news (15 items in the past 4 weeks vs 14 for WWB).
- RVMD has more recent analyst coverage (25 ratings vs 0 for WWB).
- Company
- Revolution Medicines Inc.
- Windward Bio Group AG
- Price
- -
- -
- Market cap
- $34.57B
- $1.35B
- 1M return
- -18.68%
- -
- 1Y return
- +126.61%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2026
- News (4w)
- 15
- 14
- Recent ratings
- 25
- 0
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Windward Bio Group AG
Windward Bio Group is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease, or COPD, and atopic dermatitis. Our product candidates, WIN378 and WIN027, target clinically validated disease pathways and are engineered to remain in the body for extended periods of time, enabling less frequent dosing than currently available treatments. This design feature is combined with additional properties including enhanced target affinity, dual target binding or effector function silencing. We believe our product candidates have the potential to deliver better clinical outcomes while offering the convenience of less frequent dosing than currently available treatments.
Latest RVMD
- Officer Stephen Michael Kelsey exercised 27,160 shares at a strike of $18.56 and sold $4,559,209 worth of shares (27,160 units at $167.86) as part of a pre-agreed trading plan (SEC Form 4)
- Director Flavia Borellini exercised 2,500 shares at a strike of $37.54, increasing direct ownership by 10% to 28,715 units (SEC Form 4)
- SEC Form 144 filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
- Director Borisy Alexis gifted 10,625 shares, decreasing direct ownership by 0.45% to 2,329,450 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 35,750 shares at a strike of $29.19 and sold $6,724,688 worth of shares (35,750 units at $188.10) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Mancini Anthony exercised 811 shares at a strike of $33.70 and sold $162,200 worth of shares (811 units at $200.00) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
Latest WWB
- Director David P Bonita bought $20,000,007 worth of shares (1,176,471 units at $17.00), converted options into 5,172,944 shares, exercised 216,668 shares at a strike of $0.02 and covered exercise/tax liability with 232 shares (SEC Form 4)
- Director Orbimed Advisors Llc bought $20,000,007 worth of shares (1,176,471 units at $17.00), converted options into 5,172,944 shares, exercised 216,668 shares at a strike of $0.02 and covered exercise/tax liability with 232 shares (SEC Form 4)
- Director Otello Stampacchia bought $29,750,000 worth of shares (1,750,000 units at $17.00) and converted options into 3,588,520 shares (SEC Form 4)
- Windward Bio to Participate at the Jefferies London Global Healthcare Conference
- Director Mufti Iqbal Rasool was granted 22,675 share options (SEC Form 4)
- Chief Operating Officer Harris Kevin Andrew was granted 33,206 shares, increasing direct ownership by 4% to 960,966 units (SEC Form 4)
- Chief Executive Officer Santarelli Luca was granted 815,755 employee share options (SEC Form 4)
- Chief Financial Officer D'Augusta Claudia was granted 180,160 employee share options (SEC Form 4)
- Director Bonita David P was granted 22,675 stock options (SEC Form 4)
- Director Stampacchia Otello was granted 22,675 share options (SEC Form 4)